谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

A Randomized, Double Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

David A. Wilfret,Jill Walker,Christian Voitenleitner,Sharon Baptiste-Brown,Mark Lovern,Joseph Kim,Kimberly Adkison,Brad Shotwell,Amanda Mathis,Lee Moss,Daniel Lee,Lou Yu,Jianjun Gan,Andrew Spaltenstein

Clinical Pharmacology in Drug Development（2014）

引用 4|浏览36
关键词
hepatitis C,GSK2485852,Phase I,first-time-in-human,NS5B inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要